C. Schlichting

1.7k total citations · 1 hit paper
16 papers, 1.2k citations indexed

About

C. Schlichting is a scholar working on Oncology, Immunology and Immunology and Allergy. According to data from OpenAlex, C. Schlichting has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Immunology and 3 papers in Immunology and Allergy. Recurrent topics in C. Schlichting's work include Colorectal Cancer Treatments and Studies (7 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Treatment and Pharmacology (5 papers). C. Schlichting is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Treatment and Pharmacology (5 papers). C. Schlichting collaborates with scholars based in Germany, Finland and Spain. C. Schlichting's co-authors include Michael Weis, Christophe Borg, Roger von Moos, Irmarie Reyes‐Rivera, Stefan Kubicka, Claus-Christoph Steffens, Jaafar Bennouna, Pia Österlund, Dirk Arnold and Belguendouz Bendahmane and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

C. Schlichting

16 papers receiving 1.1k citations

Hit Papers

Continuation of bevacizumab after first progression in me... 2012 2026 2016 2021 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    2012 829 citations Jaafar Bennouna, Javier Sastre et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Schlichting Germany 9 822 405 297 169 152 16 1.2k
Chiara Pierantoni Italy 16 809 1.0× 366 0.9× 154 0.5× 340 2.0× 155 1.0× 40 1.3k
Dongmei Ji China 15 539 0.7× 463 1.1× 120 0.4× 392 2.3× 163 1.1× 92 1.2k
Shigeto Maeda Japan 18 535 0.7× 189 0.5× 99 0.3× 536 3.2× 299 2.0× 63 1.5k
Takeru Wakatsuki Japan 21 1.1k 1.3× 714 1.8× 130 0.4× 356 2.1× 531 3.5× 159 1.8k
Marie‐Pierre Galais France 14 784 1.0× 662 1.6× 133 0.4× 238 1.4× 434 2.9× 38 1.3k
Janja Ocvirk Slovenia 17 1.0k 1.2× 376 0.9× 226 0.8× 156 0.9× 231 1.5× 69 1.3k
Claus-Christoph Steffens Germany 7 972 1.2× 481 1.2× 310 1.0× 148 0.9× 132 0.9× 18 1.1k
Huann-Sheng Wang Taiwan 28 1.4k 1.7× 444 1.1× 108 0.4× 424 2.5× 499 3.3× 56 2.0k
Francesco Sclafani United Kingdom 24 1.2k 1.5× 440 1.1× 253 0.9× 344 2.0× 593 3.9× 121 1.9k
Manuela Motta Italy 17 370 0.5× 198 0.5× 169 0.6× 207 1.2× 440 2.9× 26 1.3k

Countries citing papers authored by C. Schlichting

Since Specialization
Citations

This map shows the geographic impact of C. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Schlichting more than expected).

Fields of papers citing papers by C. Schlichting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Schlichting. The network helps show where C. Schlichting may publish in the future.

Co-authorship network of co-authors of C. Schlichting

This figure shows the co-authorship network connecting the top 25 collaborators of C. Schlichting. A scholar is included among the top collaborators of C. Schlichting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Schlichting. C. Schlichting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Bennouna, Jaafar, Javier Sastre, Dirk Arnold, et al.. (2012). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 14(1). 29–37. 829 indexed citations breakdown →
3.
4.
Kofler, Sieglinde, et al.. (2007). Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. Atherosclerosis. 197(1). 105–110. 19 indexed citations
5.
Schlichting, C., et al.. (2007). Involvement of Dendritic Cells in Allograft Rejection New implications of Dendritic Cell-Endothelial Cell Interactions. Mini-Reviews in Medicinal Chemistry. 7(4). 423–428. 7 indexed citations
6.
Schlichting, C., W. Schareck, & Michael Weis. (2006). Renal Ischemia–Reperfusion Injury: New Implications of Dendritic Cell–Endothelial Cell Interactions. Transplantation Proceedings. 38(3). 670–673. 37 indexed citations
7.
Nickel, Thomas, C. Schlichting, & Michael Weis. (2006). Drugs Modulating Endothelial Function after Transplantation. Transplantation. 82(Supplement 1). S41–S46. 38 indexed citations
8.
Schlichting, C., W. Schareck, & Michael Weis. (2005). Dendritic Cell Adhesion Is Enhanced on Endothelial Cells Preexposed to Calcineurin Inhibitors. Journal of Cardiovascular Pharmacology. 46(3). 250–254. 8 indexed citations
9.
Schlichting, C., et al.. (2005). Rating the severity of the medical consequences of drug-induced liver injury. Regulatory Toxicology and Pharmacology. 43(2). 134–140. 4 indexed citations
10.
Schlichting, C., W. Schareck, Thomas Nickel, & Michael Weis. (2005). Dendritic Cells as Pharmacological Targets for the Generation of Regulatory Immunosuppressive Effectors. New Implications for Allo-Transplantation. Current Medicinal Chemistry. 12(16). 1921–1930. 11 indexed citations
11.
12.
Schlichting, C., W. Schareck, & Michael Weis. (2004). Dendritic Cell Endothelium Interaction in Autoimmunity. Current Pharmaceutical Design. 10(2). 171–181. 3 indexed citations
13.
14.
Grothey, Axel, Kim Jordan, O Kellner, et al.. (2003). 295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. European Journal of Cancer Supplements. 1(5). S90–S91. 52 indexed citations
15.
Weis, Michael, C. Schlichting, Edgar G. Engleman, & John P. Cooke. (2002). Endothelial Determinants of Dendritic Cell Adhesion and Migration. Arteriosclerosis Thrombosis and Vascular Biology. 22(11). 1817–1823. 88 indexed citations
16.
Reinke, Florian, André B. P. Kuilenburg, A. H. van Gennip, et al.. (2001). Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Annals of Oncology. 12(4). 569–571. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiara Pierantoni Breakdown of academic impact, for papers by Dongmei Ji Breakdown of academic impact, for papers by Shigeto Maeda Breakdown of academic impact, for papers by Takeru Wakatsuki Breakdown of academic impact, for papers by Marie‐Pierre Galais Breakdown of academic impact, for papers by Janja Ocvirk Breakdown of academic impact, for papers by Claus-Christoph Steffens Breakdown of academic impact, for papers by Huann-Sheng Wang Breakdown of academic impact, for papers by Francesco Sclafani Breakdown of academic impact, for papers by Manuela Motta
Rankless by CCL
2026